New Health Lobby Aims to Reshape Personalized Medicine Regulation

WASHINGTON, DC – March 11, 2026 – A new advocacy group, the Personalized Health Association (PHA), announced its official launch today, positioning itself at the center of a high-stakes debate over the future of American healthcare. The federally registered 501(c)(4) organization aims to overhaul what it calls “outdated regulatory structures” to accelerate patient access to personalized, regenerative, and precision medicine.

Bringing together a coalition of clinicians, scientists, and entrepreneurs, the PHA’s stated mission is to create a modernized policy landscape where innovative, patient-specific therapies can be developed and administered safely and legally within the United States. The group’s leadership argues that current regulations stifle progress, create uncertainty for doctors, and push cutting-edge treatments offshore.

"At its core, personalized medicine is about delivering the right care to the right patient at the right time," said Jimmy St. Louis, President of the PHA, in a statement. "PHA was formed to ensure policy evolves alongside science. We believe patient-provider autonomy, supported by modern regulation and rigorous standards, is essential to advancing innovation responsibly while maintaining safety, accountability, and trust."

The Policy Battleground

The PHA enters a complex and often contentious regulatory environment. The Food and Drug Administration (FDA) has publicly committed to advancing personalized medicine but struggles to keep pace with the blistering speed of scientific discovery. Existing frameworks, designed for mass-produced pharmaceuticals, are often ill-suited for evaluating therapies tailored to an individual’s unique genetic makeup or condition.

This mismatch creates significant hurdles. Innovators face complex, time-consuming pathways to get treatments approved, particularly for therapies that combine diagnostics and therapeutics. For regulators, the challenge lies in validating the clinical utility of these new approaches while upholding stringent safety standards. The FDA itself has noted that a deeper mechanistic understanding and improved manufacturing capabilities are needed to fulfill the promise of precision medicine.

PHA’s platform directly targets these issues, advocating for “clear, workable regulatory pathways” and the “preservation of physician judgment.” The association emphasizes that its goal is not deregulation, but a re-regulation better suited for modern medicine. However, this push for reform is likely to be met with caution from regulatory bodies and medical associations that prioritize evidence-based medicine and established safety protocols. Any perceived lowering of standards could trigger opposition from groups concerned about opening the door to unproven or ineffective treatments.

Patient Choice or Pandora's Box?

Central to the PHA’s mission is the concept of “responsible access” and “patient-provider autonomy.” The organization argues that patients, in consultation with their doctors, should have greater freedom to access novel therapies. This patient-centric message resonates deeply with individuals who have exhausted conventional treatment options and see hope in personalized medicine.

"Healthcare is moving toward a future where treatment is tailored to the individual, not the average patients," noted PHA Founder Bill Moses. "The Personalized Health Association was founded to help accelerate that transition."

However, the push for greater autonomy raises critical questions about the balance between individual choice and public safety. Ethicists and public health advocates warn that without robust oversight, patients could be exposed to ineffective or harmful interventions, especially in a field prone to hype. The term “responsible access” is open to interpretation; while the PHA defines it as access within a modernized framework, critics may fear it could lead to a two-tiered system where unproven, expensive therapies are marketed to those who can pay, exacerbating health inequities.

Furthermore, the collection and use of vast amounts of personal genetic data—a cornerstone of personalized medicine—introduce significant ethical concerns regarding privacy, data security, and the potential for genetic discrimination in employment or insurance.

The Business of Health Freedom

The launch of the PHA is not just a policy initiative; it's a strategic move with significant market implications. The association’s leadership includes entrepreneurs with track records in building successful companies. Founder Bill Moses co-founded KeVita Probiotic Drinks, which was sold to PepsiCo, while President Jimmy St. Louis has founded multiple ventures in the regenerative medicine and health technology sectors. The involvement of former Montana Governor Steve Bullock, now CEO of PerfectRx, who stated PHA is committed to “visionary leadership for the paradigm shift,” signals an intent to engage at the highest levels of policy.

PHA’s focus on specific, high-growth areas—peptide therapies, regenerative medicine, compounding, and telemedicine—highlights the commercial interests at play. Each of these fields currently exists in a state of regulatory flux.

• Peptide Therapies: Popular among “biohackers” and longevity enthusiasts, peptides have recently been the subject of intense regulatory debate. After the FDA restricted their use by compounding pharmacies due to safety concerns, HHS Secretary Robert F. Kennedy Jr. just today announced a reclassification of some peptides, allowing them to be compounded with a prescription. This move, while celebrated by some, does not grant them full FDA approval and underscores the ongoing tension between access and evidence.

• Regenerative Medicine: The FDA has a framework for regenerative products, but the market is flooded with clinics marketing unapproved treatments, leading to public warnings and enforcement actions against those making unsubstantiated claims.

• Compounding: The FDA is increasing scrutiny on compounded drugs, particularly those marketed as alternatives to FDA-approved products. Recent warning letters to telehealth companies over compounded weight-loss drugs signal the agency's concern with misleading advertising.

The PHA's advocacy could pave the way for enormous growth in these sectors. By lobbying for clearer regulatory pathways, the organization could unlock billions in investment and shape a new market for tailored healthcare. The central challenge for the association will be to prove that its vision for a modernized framework can simultaneously unleash innovation, empower patients, and protect public health without compromising the scientific rigor that underpins medical progress.